Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PFIZER's Rx DIFLUCAN ONE-TABLET TREATMENT FOR VAGINAL CANDIDIASIS

This article was originally published in The Tan Sheet

Executive Summary

PFIZER's Rx DIFLUCAN ONE-TABLET TREATMENT FOR VAGINAL CANDIDIASIS represents a new competitive threat to OTC vaginal yeast infection brands, which have been beleaguered in the past year by private-label knock-offs, Pfizer's one-tablet, 150 mg Diflucan (fluconazole) dosage regimen for vaginal candidiasis was approved by FDA on June 30 with a "6P" rating by the agency, denoting a new indication of an already marketed product given a priority review. Pfizer announced the approval on July 7.

Topics

UsernamePublicRestriction

Register

PS083009

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel